Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Scholar Rock

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities4.30%
Size of stake in company3.40%
Market capitalizationUSD 3.6 bn

Sector

Neuromuscular disease

Main candidate

Apitegromab

Main indications

SMA type 2 and 3, immuno-oncology

About the company

Scholar Rock is a biotechnology company focused on developing monoclonal antibodies that are able to modulate growth factors with extraordinary selectivity. The company was founded in 2012 and is headquartered in Cambridge, Massachusetts, in the US. Scholar Rock has a technology platform based on the understanding of the extracellular activation of growth factors. The company develops antibodies to target the latent, inactive forms of growth factors to selectively and locally modulate growth factor activity within the tissue microenvironment. The lead asset, apitegromab, is an antibody targeting TGF-β currently in Phase III clinical development for Spinal Muscular Dystrophy Type 2 and 3 with data expected in late 2024.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.